Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
265 Leser
Artikel bewerten:
(1)

Preqin Ltd: Preqin announces new Head of Benchmarks and Head of Research Insights

Finanznachrichten News

Appointments set to bolster deeper performance analysis and transparency in private markets

LONDON, Jan. 30, 2024, the global leader in alternative assets data, tools, and insights, announced the appointment of key senior leaders to accelerate key products and regions that are rapidly growing, and help bridge the gaps seen in the market. Fabien Chen has taken on the newly created role of Global Head of Benchmarks, based in Singapore. Cameron Joyce, based in London, is now the Global Head of Research Insights, spearheading the creation and development of Preqin's market-leading institutional research. Additionally, Gurkan Tasoren, also based in Singapore, has been hired to drive the company's sales teams across the Asia-Pacific (APAC) region as Head of Sales, APAC.

With private markets being a historically opaque industry, fund and asset-level performance analysis and benchmarking continue to be a challenge for market professionals. This is where Preqin's private market capital benchmarks make the difference by giving investors, fund managers and service providers access to independent, reliable, timely and transparent performance data. These solutions allow market professionals to drive meaningful performance analysis and make informed investment decisions, as the most comprehensive and representative benchmarks across all alternatives asset classes. This ultimately helps the industry become more efficient and transparent. Preqin's fund performance benchmarks have been recognized by a third party as the market leader* and are best positioned to provide greatest granularity and named performance data.

Fabien Chen, as the new Head of Benchmarks, will play a pivotal role in further developing Preqin's suite of global benchmark solutions and propel the teams to significantly expand the range, scope and transparency. Previously, Fabien led teams at McKinsey before joining Preqin in March 2022 as Head of APAC Strategy. Fabien's strong customer focus, coupled with a deep understanding of the alternative assets industry, will ensure the Benchmarks become even more relevant and effective for the industry.

Cameron Joyce, who was a Senior Vice President on Preqin's Research Insights team since 2020, will now lead the team of expert researchers. The industry-leading institutional research provides more than 100 annual reports, like the "Future of Alts"market studies that are widely referenced, leveraging Preqin's independent, data-driven view of the alternatives market, investor sentiment, private market valuations, fees and terms, and industry compensation. The valuable content and actionable insights mean readers are empowered to formulate their own perspectives and inform their investment decisions. Cameron previously worked in asset allocation, investment research and fund selection roles.

Additionally, Gurkan Tasoren joins Preqin as Head of Sales, APAC and will drive strategic growth initiatives across the region. He is well positioned to foster lasting client relationships, bringing more than two decades of experience in the global fintech industry, with extensive prior leadership experience at Bloomberg. Gurkan will be a trusted partner for clients, helping them navigate the current challenging market conditions and evolving landscape.

Reflecting on these appointments, Christoph Knaack, CEO, at Preqin, says, "Fabien, Cameron and Gurkan are well-established professionals within their respective fields, each having a deep appreciation of the complexities of private markets and issues that our clients face. I am confident that these appointments will contribute significantly to our continued success and help us improve our standing as the source of essential alternatives data and insights, trusted by every financial professional in the alternatives industry."

If you would like more information or have any questions, please get in touch with Mimi Celeste Taylor mimiceleste.taylor@preqin.com

Notes to the editors

* Probitas Partners' 2024 Institutional Investors Private Equity Survey December 2023
______________________________________________________________________________________________

About Preqin

Preqin, the Home of Alternatives, empowers financial professionals who invest in or allocate to alternatives with essential data and insight to make confident decisions. It supports them throughout the entire investment lifecycle with critical information and leading analytics solutions. The company has pioneered rigorous methods of collecting private data for 20 years, enabling more than 200,000 professionals globally to streamline how they raise capital, source deals and investments, understand performance, and stay informed. For more information visit www.preqin.com.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.